2nd Jun 2014 05:53
LONDON (Alliance News) - GlaxoSmithKline PLC has completed a deal to develop new cancer drugs with a UK biotech company, which could be worth over USD350 million, the Financial Times reports Monday, quoting Adaptimmune Ltd Chief Executive James Noble.
Glaxo is expected to announce a deal on Monday in which it will pay Adaptimmune the cash over the next seven years, subject to certain development milestones being met, the FT says. The companies will work together to develop cell-based cancer therapies that involve re-engineering white blood cells to strengthen the body's ability to fight tumours.
http://www.ft.com/cms/s/0/c141638c-e96b-11e3-99ed-00144feabdc0.html#axzz33SRUEYww
By Tom McIvor; [email protected]; @TomMcIvor1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline